The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Litvinov V.V.

Perm State Medical University named after academician E.A. Wagner

Freynd G.G.

Perm State Medical University named after academician E.A. Wagner

Clinical and morphologic characterization of Pick’s dementia: case report and review of the literature

Authors:

Litvinov V.V., Freynd G.G.

More about the authors

Read: 1865 times


To cite this article:

Litvinov VV, Freynd GG. Clinical and morphologic characterization of Pick’s dementia: case report and review of the literature. Russian Journal of Archive of Pathology. 2024;86(4):51‑57. (In Russ.)
https://doi.org/10.17116/patol20248604151

References:

  1. Brodaty H, Breteler MM, DeKosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg PA, Scheltens P, De Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc. 2011;59(5):923-927.  https://doi.org/10.1111/j.1532-5415.2011.03365.x
  2. Carlos AF, Josephs KA. Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100 years. J Neurol. 2022;269(8):4030-4054. https://doi.org/10.1007/s00415-022-11073-3
  3. Vieira RT, Caixeta L, Machado S, Silva AC, Nardi AE, Arias-Carrión O, Carta MG. Epidemiology of early-onset dementia: a review of the literature. Clin Pract Epidemiol Ment Health. 2013;9:88-95.  https://doi.org/10.2174/1745017901309010088
  4. Kertesz A. Pick complex — historical introduction. Alzheimer Dis Assoc Disord. 2007;21(4):S5-S7.  https://doi.org/10.1097/WAD.0b013e31815bf65a
  5. Mann DMA, Snowden JS. Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype. Brain Pathol. 2017;27(6):723-736.  https://doi.org/10.1111/bpa.12486
  6. Shpilyukova YuA, Fedotova EYu, Illarioshkin SN. Genetic diversity of frontotemporal dementia. Molecular Biology. 2020;54(1): 17-28. (In Russ.). https://doi.org/10.31857/S0026898420010139
  7. Whitwell JL, Josephs KA, Rossor MN, Stevens JM, Revesz T, Holton JL, Al-Sarraj S, Godbolt AK, Fox NC, Warren JD. Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol. 2005;62(9):1402-1408. https://doi.org/10.1001/archneur.62.9.1402
  8. Irwin DJ, Brettschneider J, McMillan CT, Cooper F, Olm C, Arnold SE, Van Deerlin VM, Seeley WW, Miller BL, Lee EB, et al. Deep clinical and neuropathological phenotyping of Pick disease. Ann Neurol. 2016;79(2):272-287.  https://doi.org/10.1002/ana.24559
  9. Hofmann JW, Seeley WW, Huang EJ. RNA binding proteins and the pathogenesis of frontotemporal lobar degeneration. Annu Rev Pathol. 2019;14:469-495.  https://doi.org/10.1146/annurev-pathmechdis-012418-012955
  10. Virgilio E, De Marchi F, Contaldi E, Dianzani U, Cantello R, Mazzini L, Comi C. The role of tau beyond Alzheimer’s disease: a narrative review. Biomedicines. 2022;10(4):760.  https://doi.org/10.3390/biomedicines10040760
  11. Hardy J, Rogaeva E. Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. Exp Neurol. 2014; 262(Pt. B):75-83.  https://doi.org/10.1016/j.expneurol.2013.11.006
  12. Buratti E, Baralle FE. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol. 2010;7(4): 420-429.  https://doi.org/10.4161/rna.7.4.12205
  13. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122(1):111-113.  https://doi.org/10.1007/s00401-011-0845-8
  14. Josephs KA, Whitwell JL, Parisi JE, Petersen RC, Boeve BF, Jack CR Jr, Dickson DW. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol. 2010;17(7):969-975.  https://doi.org/10.1111/j.1468-1331.2010.02975.x
  15. Gelon PA, Dutchak PA, Sephton CF. Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease. Front Mol Neurosci. 2022;15:1000183. https://doi.org/10.3389/fnmol.2022.1000183
  16. Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A, Jones M, Neary D, Mann DM, Pickering-Brown S. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):497-505.  https://doi.org/10.3109/21678421.2015.1074700
  17. Beck J, Rohrer JD, Campbell T, Isaacs A, Morrison KE, Goodall EF, Warrington EK, Stevens J, Revesz T, Holton J, et al. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain. 2008;131(Pt. 3):706-720.  https://doi.org/10.1093/brain/awm320
  18. Lall D, Baloh RH. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. J Clin Invest. 2017; 127(9):3250-3258. https://doi.org/10.1172/JCI90607
  19. Devenney E, Hornberger M, Irish M, Mioshi E, Burrell J, Tan R, Kiernan MC, Hodges JR. Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile. JAMA Neurol. 2014;71(3):331-339.  https://doi.org/10.1001/jamaneurol.2013.6002
  20. Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI, Gearing M, Glass JD, Seyfried NT. A proteomic network approach across the ALS‐FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 2018;10(1):48-62.  https://doi.org/10.15252/emmm.201708202
  21. King AE, Woodhouse A, Kirkcaldie MT, Vickers JC. Excitotoxicity in ALS: overstimulation, or overreaction? Exp Neurol. 2016;275(Pt. 1):162-171.  https://doi.org/10.1016/j.expneurol.2015.09.019
  22. Coyle JT, Balu D, Wolosker H. D-Serine, the Shape-Shifting NMDA receptor co-agonist. Neurochem Res. 2020;45(6):1344-1353. https://doi.org/10.1007/s11064-020-03014-1
  23. Piguet O, Halliday GM, Reid WG, Casey B, Carman R, Huang Y, Xuereb JH, Hodges JR, Kril JJ. Clinical phenotypes in autopsy-confirmed Pick disease. Neurology. 2011;76(3):253-259.  https://doi.org/10.1212/WNL.0b013e318207b1ce
  24. Dickson DW. Pick’s disease: a modern approach. Brain Pathol. 1998;8(2):339-354.  https://doi.org/10.1111/j.1750-3639.1998.tb00158.x
  25. Kovacs GG, Rozemuller AJ, Van Swieten JC, Gelpi E, Majtenyi K, Al-Sarraj S, Troakes C, Bódi I, King A, Hortobágyi T, et al. Neuropathology of the hippocampus in FTLD-Tau with Pick bodies: a study of the BrainNet Europe Consortium. Neuropathol Appl Neurobiol. 2013;39(2):166-178.  https://doi.org/10.1111/j.1365-2990.2012.01272.x
  26. Hayes LR, Kalab P. Emerging therapies and novel targets for TDP-43 proteinopathy in ALS/FTD. Neurotherapeutics. 2022;19(4): 1061-1084. https://doi.org/10.1007/s13311-022-01260-5
  27. Ono M, Komatsu M, Ji B, Takado Y, Shimojo M, Minamihisamatsu T, Warabi E, Yanagawa T, Matsumoto G, Aoki I, et al. Central role for p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy. Aging Cell. 2022;21(7):e13615. https://doi.org/10.1111/acel.13615
  28. Fu H, Possenti A, Freer R, Nakano Y, Hernandez Villegas NC, Tang M, Cauhy PVM, Lassus BA, Chen S, Fowler SL, et al. A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nat Neurosci. 2019;22(1):47-56.  https://doi.org/10.1038/s41593-018-0298-7
  29. Mandrioli J, Crippa V, Cereda C, Bonetto V, Zucchi E, Gessani A, Ceroni M, Chio A, D’Amico R, Monsurrò MR, et al. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). BMJ Open. 2019;9(5):e028486. https://doi.org/10.1136/bmjopen-2018-028486
  30. Pfeiffer RM, Mayer B, Kuncl RW, Check DP, Cahoon EK, Rivera DR, Freedman DM. Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3-4):235-245.  https://doi.org/10.1080/21678421.2019.1682613
  31. Milani M, Mammarella E, Rossi S, Miele C, Lattante S, Sabatelli M, Cozzolino M, D’Ambrosi N, Apolloni S. Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis. J Neuroinflammation. 2021;18(1):132.  https://doi.org/10.1186/s12974-021-02184-1

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.